

This article was downloaded by:

On: 28 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

Anti-Cocaine Catalytic Antibodies

Rowena E. Almonte; Shixian Deng; Paloma De Prada; Milan N. Stojanovic; Donald W. Landry

To cite this Article Almonte, Rowena E. , Deng, Shixian , De Prada, Paloma , Stojanovic, Milan N. and Landry, Donald W.(1999) 'Anti-Cocaine Catalytic Antibodies', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 144: 1, 239 — 241

To link to this Article: DOI: 10.1080/10426509908546226

URL: <http://dx.doi.org/10.1080/10426509908546226>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.


Anti-Cocaine Catalytic Antibodies

ROWENA E. ALMONTE, SHIXIAN DENG, PALOMA DE PRADA,
MILAN N. STOJANOVIC and DONALD W. LANDRY

*Department of Medicine, Columbia University, College of Physicians & Surgeons,
630 W. 168th Street, New York, NY 10032*

Over 50,000,000 Americans have used cocaine (1) since 1980 and approximately 2,000,000 are presently addicted with disastrous medical and social consequences.¹ At present, no efficient drug therapy is available for the management of cocaine abuse and dependence. Cocaine is hypothesized to exert its addictive effect by blocking a transport protein for the neurotransmitter dopamine, and the difficulties inherent in blocking a blocker may in part explain the failure to develop a useful therapeutic agent. One alternative to the classical receptor antagonist approach would be a circulating catalytic antibody that could degrade cocaine and interfere with the delivery of the drug to the central nervous system. To obtain antibodies able to catalyze the hydrolysis of cocaine to the inactive products, ecgonine methyl ester (2) and benzoic acid (3), we synthesized a series of stable phosphonate monoester transition state analogs for benzoyl esterolysis (4a-c). With these immunogens we elicited the first artificial enzymes able to degrade cocaine *in vitro*.^{2,3}

The most active catalytic antibody, Mab 15A10,³ displayed a hydrolysis rate acceleration of 2.4×10^4 , a turnover rate of 2 min^{-1} and a K_m of $220 \mu\text{M}$. These parameters were sufficient to commence preclinical studies in animal models of addiction and overdose.⁴ In a model of cocaine overdose, this antibody protected rats from the lethal effects of cocaine, while in a comparative study, a non-catalytic cocaine-binding antibody did not reduce cocaine toxicity.



Consistent with catalytic degradation, the concentration of ecgonine methyl ester was increased tenfold in the plasma of rats that simultaneously received Mab 15A10 and cocaine. Also, in a rat model of cocaine addiction, Mab 15A10 blocked completely and specifically the reinforcing effect of cocaine. A humanized version of Mab 15A10 will allow evaluation of this approach in a primate self-administration model as a prelude to clinical trials.

Our effort to improve the activity of the first artificial enzymes to degrade cocaine is focused on the synthesis of novel transition-state analogs, the mutagenesis of our most active antibody, and the development of high throughput screening assays for the cocaine esterase activity.

Acknowledgments

The support of the Counterdrug Technology Assessment Center at the office of National Drug Control Policy to DWL, and the NIH postdoctoral fellowship to MNS are gratefully acknowledged.

References

- [1] The National Drug Control Strategy, Office of the National Drug Control Policy, Executive Office of the President of the United States, Washington (1996), p. 41.
- [2] D. W. Landry, K. Zhao, G. X. Yang, M. Glickman, T. M. Georgiadis, *Science*, **259**, 1899 (1993).
- [3] G. X. Yang, J. Chun, H. Arakawa-Uramoto, X. Wang, M.A. Gawinowicz, K. Zhao, D. W. Landry, *J. Am. Chem. Soc.*, **118**, 5881 (1996).

- [4] B. Mets, G. Winger, C. Cabrera, S. Seo, S. Jamdar, G. W. Yang, K. Zhao, J. R. Briscoe, R. E. Almonte, J. H. Woods, D. W. Landry, *Proc. Nat. Ac. Sci.*, in press (1998).